RxDoctor Payments DataLook up a doctor →

Howard Huang, MD

Pulmonary Disease · Houston, TXNPI 1396896189

Payments from drug & device makers

$1,331,541in general payments, 2019–2025

Across 314 payments — averaging $4240.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$608K
  • Eli Lilly$265K
  • Boehringer Ingelheim$150K
  • Paragonix Technologies, Inc.$142K
  • E.r. Squibb & Sons, L.L.C.$114K
  • Astrazeneca UK Limited$15K
  • plus $38K from 30 others
$64,819in research payments, 2019–2025

Across 3 payments — averaging $21,606 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$61K
  • United Therapeutics Corporation$4K

What the payments were for

  • Consulting fees$52,09327%
  • Speaking & faculty fees$110,92857%
  • Travel & lodging$22,87212%
  • Food & beverage$8,3934%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,331,541 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$70,859
Medicare patients
315
Services billed
2,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4623$137,532
Gamunex-CImmune Globul G/Gly/Iga Avg 4619$111,033
Valganciclovir Hcl228$63,510
EliquisApixaban78$59,570
Atovaquone113$56,099
Voriconazole87$30,730
Posaconazole29$24,571
Tacrolimus155$20,005
Envarsus XrTacrolimus31$18,848
Enoxaparin Sodium60$12,449
TradjentaLinagliptin16$11,517
Mycophenolate Mofetil52$9,000
Mycophenolic AcidMycophenolate Sodium30$7,454
Itraconazole18$6,017
Sirolimus19$5,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$163$111,03319 claims
PfizerEliquis$61$59,57078 claims
Boehringer IngelheimTradjenta$150,183$11,51716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →